R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Journal of Pharmacology

• Publication date

  2005-01-04

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.EJPHAR.2004.11.013PMID 15627439
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia.

  2001cited by this paper
• Anakinra: interleukin-1 receptor antagonist therapy for rheumatoid arthritis.

  2001cited by this paper
• Severe inflammatory arthritis and lymphadenopathy in the absence of TNF.

  2001cited by this paper
• What is the natural history of rheumatoid arthritis?

  2001cited by this paper
• FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis

  2001cited by this paper
• Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys.

  2001cited by this paper
• Prostaglandin E2 Regulates the Level and Stability of Cyclooxygenase-2 mRNA through Activation of p38 Mitogen-activated Protein Kinase in Interleukin-1β-treated Human Synovial Fibroblasts*

  2001cited by this paper
• SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.

  2001cited by this paper
• Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.

  2001cited by this paper
• The type II decoy receptor of IL‐1 inhibits murine collagen‐induced arthritis

  2000cited by this paper
• The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8)

  2000cited by this paper
• Effects of pentoxifylline and nabumetone on the serum levels of IL-1β and TNFα in rats with adjuvant arthritis

  2000cited by this paper
• TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide

  2000cited by this paper
• Evaluation of TNF-α and IL-1 Blockade in Collagen-Induced Arthritis and Comparison with Combined Anti-TNF-α/Anti-CD4 Therapy1

  2000cited by this paper
• Induction of collagenase-3 (MMP-13) in rheumatoid arthritis synovial fibroblasts.

  2000cited by this paper
• Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis.

  2000cited by this paper
• Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

  2000cited by this paper
• Anti-arthritic effect of methotrexate: is it really mediated by adenosine?

  2000cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Role of Mitogen-Activated Protein Kinase Cascades in Mediating Lipopolysaccharide-Stimulated Induction of Cyclooxygenase-2 and IL-1β in RAW264 Macrophages1

  2000cited by this paper
• Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

  1999cited by this paper
• Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages.

  1999cited by this paper
• Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

  1999cited by this paper
• Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate.

  1999cited by this paper
• Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice.

  1999cited by this paper
• IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.

  1999cited by this paper
• Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis.

  1999cited by this paper
• Etanercept Therapy in Rheumatoid Arthritis

  1999cited by this paper
• p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials.

  1999cited by this paper
• Interleukin 6 Is Required for the Development of Collagen-induced Arthritis

  1998cited by this paper
• Pyrroles and other heterocycles as inhibitors of p38 kinase.

  1998cited by this paper
• SB202190, a selective inhibitor of p38 mitogen‐activated protein kinase, is a powerful regulator of LPS‐induced mRNAs in monocytes

  1998cited by this paper
• 6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.

  1998cited by this paper
• Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis.

  1998cited by this paper
• The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.

  1997cited by this paper
• A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

  1997cited by this paper
• MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway

  1996cited by this paper
• Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.

  1996cited by this paper
• Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids.

  1994cited by this paper
• Elevated levels of TNF in the joints of adjuvant arthritic rats.

  1993cited by this paper
• Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

  1993cited by this paper
• Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.

  1993cited by this paper
• Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

  1992cited by this paper
• cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.

  1992cited by this paper
• Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts.

  1992cited by this paper
• Synovial tissue macrophage as a source of the chemotactic cytokine IL-8.

  1991cited by this paper
• Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis.

  1990cited by this paper
• Interleukin-6 serum levels correlate with footpad swelling in adjuvant-induced arthritic Lewis rats treated with cyclosporin A or indomethacin.

  1990cited by this paper
• Characteristics of tumor necrosis factor production in rheumatoid arthritis.

  1989cited by this paper
• Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

  1989cited by this paper
• The effect of immunomodulating drugs on adjuvant-induced arthritis in Lewis rats

  1989cited by this paper
• Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis.

  1988cited by this paper
• Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis.

  1988cited by this paper
• Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides.

  1988cited by this paper
• Endotoxins and disease mechanisms.

  1987cited by this paper
• Models of arthritis and the search for anti-arthritic drugs.

  1983cited by this paper
• Evaluation of analgesic agents in rats with adjuvant arthritis.

  1975cited by this paper
• HEPATITIS B NOT TRANSMISSIBLE VIA FÆCAL-ORAL ROUTE

  1975cited by this paper
• Comparative bioassay of drugs in adjuvant-induced arthritis in rats: flufenamic acid, mefenamic acid, and phenylbutazone.

  1969cited by this paper
• Type II Collagen-induced Arthritis in Mice

  year unknowncited by this paper

• Inhibition of the P38 MAPK/NLRP3 Pathway Mitigates Cognitive Dysfunction and Mood Alterations in Aged Mice after Abdominal Surgery Plus Sevoflurane.

  2024cites this paper
• RIP2 knockdown inhibits cartilage degradation and oxidative stress in IL-1β-treated chondrocytes via regulating TRAF3 and inhibiting p38 MAPK pathway.

  2021cites this paper
• Therapeutic effects of triptolide from Tripterygium wilfordii Hook. f. on interleukin-1-beta-induced osteoarthritis in rats.

  2020cites this paper
• Antioxidant defenses and non-specific immunity at enzymatic and transcriptional levels in response to dietary carbohydrate in a typical carnivorous fish, hybrid grouper (Epinephelus fuscoguttatus ♀ × E. lanceolatus ♂).

  2020cites this paper
• Myeloid p38 MAPK signaling in intestinal homeostasis, inflammation and tumorigenesis = Señalización por la MAPK p38 de células mieloides en la homeostasis, inflamación y tumorogénesis intestinal

  2017cites this paper
• Intestinal immune function, antioxidant status and tight junction proteins mRNA expression in young grass carp (Ctenopharyngodon idella) fed riboflavin deficient diet.

  2015cites this paper
• A store‐operated calcium channel inhibitor attenuates collagen‐induced arthritis

  2015cites this paper
• Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats.

  2014cites this paper
• Alternative p38 MAPKs Are Essential for Collagen‐Induced Arthritis

  2014cites this paper
• Dietary tryptophan modulates intestinal immune response, barrier function, antioxidant status and gene expression of TOR and Nrf2 in young grass carp (Ctenopharyngodon idella).

  2014cites this paper
• p38 MAPK: a potential target of chronic pain.

  2014cites this paper
• Mitogen-activated protein kinase and natural phenolic compounds in cardiovascular remodeling

  2012cites this paper
• Molecular Biology of the Host-Microbe Interaction in Periodontal Diseases

  2012cites this paper
• MAPK Usage in Periodontal Disease Progression

  2012cites this paper
• Anti-Inflammatory/Analgesics: An In-Depth Look at p38 MAP Kinases

  2011cites this paper
• Role of Nag-1 and p75NTR in non-steroidal anti-inflammatory drug inhibition of prostate cancer cell migration

  2011cites this paper
• Tyr³²³-dependent p38 activation is associated with rheumatoid arthritis and correlates with disease activity.

  2011cites this paper
• In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model: a pre-clinical study.

  2010cites this paper
• Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?

  2010cites this paper
• Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 3.

  2010cites this paper
• Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1β-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice

  2009cites this paper
• The p 38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

  2009cites this paper
• The potential of p38 MAPK inhibitors to modulate periodontal infections.

  2009cites this paper
• Ligularia fischeri leaf extract suppresses proinflammatory mediators in SW982 human synovial cells

  2009cites this paper
• The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

  2009cites this paper
• Mechanisms of the joint-protective effects of p38 MAPK inhibitors in rodent arthritis

  2008cites this paper
• Title Page: Pamapimod, A Novel p38 MAP Kinase Inhibitor: Preclinical Analysis of Efficacy and Selectivity

  2008cites this paper
• β-cell regeneration to treat Type 1 diabetes mellitus

  2008cites this paper
• Targeting signaling pathways with small molecules to treat autoimmune disorders

  2008cites this paper
• P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis

  2008cites this paper
• Pamapimod, a Novel p38 Mitogen-Activated Protein Kinase Inhibitor: Preclinical Analysis of Efficacy and Selectivity

  2008cites this paper
• C‐Jun NH2 terminal kinase (JNK) is an essential mediator of Toll‐like receptor 2‐induced corneal inflammation

  2008cites this paper
• Protein kinases as small molecule inhibitor targets in inflammation.

  2007cites this paper
• Collagenase gene regulation by pro-inflammatory cytokines in cartilage.

  2007cites this paper
• Cellular Signaling in Cartilage Tissue Engineering

  2007cites this paper
• In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice

  2007cites this paper
• Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways.

  2007cites this paper
• Novel p38 mitogen-activated protein kinase inhibitor R-130823 protects cartilage by down-regulating matrix metalloproteinase-1,-13 and prostaglandin E2 production in human chondrocytes.

  2006cites this paper
• p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis.

  2006cites this paper
• Peroxynitrite-modified collagen-II induces p38/ERK and NF-kappaB-dependent synthesis of prostaglandin E2 and nitric oxide in chondrogenically differentiated mesenchymal progenitor cells.

  2006cites this paper
• Infliximab neutralizes the suppressive effect of TNF-alpha on expression of extracellular-superoxide dismutase in vitro.

  2006cites this paper
• UNIVERSIDADE ESTADUAL PAULISTA - UNESP FACULDADE DE ODONTOLOGIA DE ARARAQUARA

  2006cites this paper
• The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells

  2006cites this paper
• Therapies for rheumatoid arthritis: hope springs eternal.

  2005cites this paper
• Novel p38 MAP kinase inhibitor R-130823 suppresses IL-6, IL-8 and MMP-13 production in spheroid culture of human synovial sarcoma cell line SW 982.

  2005cites this paper
• MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits.

  2005cites this paper